BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Eikon Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Eikon Therapeutics's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06246110-2115@assetmemo.bio
DTSTAMP:20261121T010136Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Resiquimod: Phase 2 readout est. (NCT06246110)
DESCRIPTION:Resiquimod\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Pat
 ients With Stage 4 NSCLC\nEstimated primary completion: December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/resiquimod#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06246110
URL:https://assetmemo.bio/drug/resiquimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697301-2115@assetmemo.bio
DTSTAMP:20261121T010136Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Resiquimod: Phase 2/3 readout est. (NCT06697301)
DESCRIPTION:Resiquimod\, phase 2/3\, Melanoma.\nStudy: Safety and Efficacy 
 of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Th
 erapy in Patients With Advanced Melanoma.\nEstimated primary completion: D
 ecember 2035. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/resiqui
 mod#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06697301
URL:https://assetmemo.bio/drug/resiquimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365319-2115@assetmemo.bio
DTSTAMP:20261121T010136Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Resiquimod: Phase 2/3 readout est. (NCT07365319)
DESCRIPTION:Resiquimod\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and
  Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.\nEs
 timated primary completion: 31 December 2035. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/resiquimod#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07365319
URL:https://assetmemo.bio/drug/resiquimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
